Anzeige
Mehr »
Login
Donnerstag, 04.06.2020 Börsentäglich über 12.000 News von 628 internationalen Medien
Charttechnischer Ausbruch und DIE wirklich bedeutende News in Kürze!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14M2J ISIN: IE00BTN1Y115 Ticker-Symbol: 2M6 
Tradegate
04.06.20
19:20 Uhr
85,72 Euro
-0,66
-0,76 %
1-Jahres-Chart
MEDTRONIC PLC Chart 1 Jahr
5-Tage-Chart
MEDTRONIC PLC 5-Tage-Chart
RealtimeGeldBriefZeit
85,3385,6619:41
85,3185,8119:40
GlobeNewswire (Europe)
521 Leser
Artikel bewerten:
(2)

Medtronic plc: FDA Classifies Medtronic Sherpa Delivery Catheter Field Action Initiated in March 2019 as Class I Recall

DUBLIN, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) has classified the company's voluntary field action initiated in March 2019 related to the 6F Sherpa NX Active Coronary Guide Catheter as a Class I recall. The catheter is used during coronary and peripheral interventional procedures. This issue does not affect the Medtronic Launcher Coronary Guide Catheter or other Medtronic coronary stents, balloons or implantable devices.

In response to receiving six complaints, Medtronic conducted a thorough investigation of certain lots of the product and determined that the affected catheters may have a potential to lose outer material from a distal component that could result in the underlying stainless-steel braid wires being exposed after insertion. While Medtronic has received no reports of patient injuries, as a precaution, Medtronic has voluntarily recalled all models of the 6F Sherpa NX Active Catheters due to potential patient risks associated with this issue. The issue has been reported to FDA and other regulatory authorities. Customers using the catheter have been asked to return all affected inventory to Medtronic.

Health care professionals can direct questions to their Medtronic Field Representative or Medtronic Customer Service at +1-888-283-7868. Patients may contact Medtronic Cardiovascular Patient Services at +1-877-526-7890 (Monday-Friday, 7:30am-5pm Central Time), and may also view information about this action at http://newsroom.medtronic.com/ (http://newsroom.medtronic.com/).

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA: Online at http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm (http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm) (form available to fax or mail), or call FDA at +1-800-FDA-1088.

About Medtronic
Medtronic plc (www.medtronic.com (http://www.medtronic.com/)), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-


Joey Lomicky
Public Relations
+1 -763-526-2494

Ryan Weispfenning
Investor Relations
+1-763-505-4626

MEDTRONIC-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2019 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.